FDA Grants Accelerated Approval to Etcamah (camizestrant) in Combination with a CDK4/6 Inhibitor for the Treatment of Advanced HR-Positive Breast Cancer

Sep 7, 2026 - 06:00
 0  0
September 4, 2026 -- AstraZeneca’s Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0